key: cord-0712672-ar5jiotm
authors: Lingel, Holger; Meltendorf, Stefan; Billing, Ulrike; Thurm, Christoph; Vogel, Katrin; Majer, Christiane; Prätsch, Florian; Roggenbuck, Dirk; Heuft, Hans-Gert; Hachenberg, Thomas; Feist, Eugen; Reinhold, Dirk; Brunner-Weinzierl, Monika C.
title: Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals
date: 2021-06-21
journal: J Autoimmun
DOI: 10.1016/j.jaut.2021.102682
sha: cbae0a33726b335f292823fce886eaac485434f1
doc_id: 712672
cord_uid: ar5jiotm

The variability in resolution of SARS-CoV-2-infections between individuals neither is comprehended, nor are the long-term immunological consequences. To assess the long-term impact of a SARS-CoV-2-infection on the immune system, we conducted a prospective study of 80 acute and former SARS-CoV-2 infected individuals and 39 unexposed donors to evaluate autoantibody responses and immune composition. Autoantibody levels against cyclic citrullinated peptide (CCP), a specific predictor for rheumatoid arthritis (RA), were significantly (p = 0.035) elevated in convalescents only, whereas both acute COVID-19 patients and long-term convalescents showed critically increased levels of anti-tissue transglutaminase (TG), a specific predictor of celiac disease (CD) (p = 0.002). Both, anti-CCP and anti-TG antibody levels were still detectable after 4–8 months post infection. Anti-TG antibodies occurred predominantly in aged patients in a context of a post-SARS-CoV-2-specific immune composition (R(2) = 0.31; p = 0.044). This study shows that increased anti-CCP and anti-TG autoantibody levels can remain long-term after recovering even from mildly experienced COVID-19. The inter-relationship of the lung as viral entry side and RA- and CD-associated autoimmunity indicates that a SARS-CoV-2-infection could be a relevant environmental factor in their pathogenesis.

J o u r n a l P r e -p r o o f

COVID-19 is caused by severe acute respiratory syndrome-like coronavirus 2 (SARS-CoV-2) [1, 2] that has so far claimed over 3 million lives worldwide and 142.5 million confirmed SARS-CoV-2 infected persons [3] . The disease course of COVID-19 is extremely variable among acutely infected individuals as well as convalescents and remains poorly understood. Although most of the infected individuals show mild symptoms, some convalescents develop long-lasting symptoms such as fatigue, loss of smell, and chronic muscle pain. As autoantibodies against IFNs [4] , anticoagulants [5] and phospholipids have been observed in severely ill COVID-19 patients [6] , and loss of smell as well as fatigue is a typical symptom in some of the autoimmune diseases [7] , the question arises whether SARS-CoV-2 infections could induce and/or contribute to autoimmune pathologies [8] , e.g. rheumatic diseases, such as rheumatoid arthritis (RA), Kawasaki-like disease (KD) [9] , or coeliac disease (CD) [4, 10] . Due to the long-term effects and the limited number of currently available treatment options for the therapy of COVID-19 and the chronic nature of autoimmune diseases, it seems reasonable to clarify this relationship.

The control of SARS-CoV-2 infection is decisively determined by the host´s immune response.

During acute severe COVID-19, lymphopenia and exhaustion of T-cells occurs, but also lifethreatening hyper-reactivity of the immune response known as "cytokine storm" [11, 12] . SARS-CoV-2 initiates intense CD4 and CD8 T-cell responses and induces antibodies to SARS-CoV-2 proteins such as Spike (S), membrane, and nucleocapside protein (N) [13, 14] . Indeed, there appears to be a strong correlation between levels of antibodies against the S-and N-proteins and T cell responses specific for these proteins [13] and disease severity in COVID-19 patients [15] . Three weeks post onset of infection, CD4 central memory T-cells (T CM ) have been suggested to be the major responding population [14] and accumulated evidence indicates that the composition of T-cell subpopulations of convalescents are still altered months after resolving a SARS-CoV-2 infection [16] .

Autoimmune diseases have a worldwide prevalence of approximately 4% [17] . For several entities, such as RA and CD, women show increased susceptibility. Accumulated evidence indicates J o u r n a l P r e -p r o o f that autoantibodies contribute or even initiate autoimmune pathology [18, 19] . In genetically prone patients with RA, a specific autoimmune response occurs against post-translationally modified antigens e.g. by citrullination. The physiologic process of citrullination occurs at sites of inflammation and is driven by peptidyl-arginine-deiminase (PAD) enzymes, which are inducible by environmental factors such as smoking or viral infections. The current widely accepted model of anti-citrullinated peptide/protein antibody (ACPA) induction locates this process to mucosal tissues like the lungs [18, 20] . Similarly to the occurrence of ACPAs in RA, specific autoantibodies are used as surrogate markers of pathologic processes e.g. in systemic lupus erythematosus (SLE), Scleroderma, antiphospholipid syndrome (APLS), and also for CD [10] . In addition, while elevated levels of IgA specific antibodies against transglutaminase (TG) are shown to be associated with CD, they also appear to be associated with a higher mortality risk in males of >50 years of age whose death is due to respiratory failure [21] .

It is of utmost importance to diagnose the onset of autoimmune processes as early as possible as advances have been made by using the "window-of-opportunity" for treatment [22, 23] . In the case of rheumatic diseases, it is known that the first immunological signs of the disease, namely induction of autoantibodies such as ACPA, can be observed several years before the onset of clinical symptoms [24] . In this context, viral infections have been proposed as one triggering factor. In this prospective study in convalescent adults having recovered from mild SARS-CoV-2 infections, we provide first evidence for specific and long-lasting autoimmune responses.

This study was formerly approved by the Ethics Board of the University of Magdeburg In our study, 68 COVID-19 convalescent individuals with a history of mild disease and 39 volunteers considered as being unexposed due to being negative for anti-SARS-CoV-2 S-and Nantibodies, devoid of COVID-19 specific symptoms and acquired in a region and time with less than 10 infected persons per 100,000 inhabitants were examined from April to November 2020, as well as 12 acute severely ill patients from December 2020 to January 2021 (see Table 1 ). Different study group sizes were processed, as healthy individuals were recruited within a limited time window with less than 10 infected persons per 100,000 inhabitants during spring 2020. 68 convalescent COVID-19

patients were tested positive for SARS-CoV-2 RNA and/or for anti-SARS-CoV-2 Spike antibodies. 19 of these patients that showed anti-S antibody levels below 12 ng/ml were tested as anti-S antibody negative and vice versa 49 positive. All healthy donors were tested negative for anti-SARS-CoV-2

antibodies. None of the convalescents or healthy subjects had a history of autoimmune disease.

Serum separation was performed from blood samples by centrifugation (5 min at 3500 rpm) and Peripheral blood mononuclear cells (PBMC) were isolated by density-gradient sedimentation using Pancoll (PAN Biotech) as previously described [25] . 1.5 × 10 5 PBMCs were stained using specific antibodies against following molecules (clone names in parentheses): CD4 (RPA-T4), CD3 (SK7), CD8

(HIT8a), CD45RO (UCHL1), CCR7 (G043H7), KLRG1 (1D11) and CTLA-4 (L3D10) (all Biolegend). Cell samples were analyzed by polychromatic flow cytometry using the FACS Canto II and FACSDiva software (all from BD Biosciences) and the data analyzed using Flow Jo (FlowJo). 

To evaluate long lasting autoimmune responses initiated by a SARS-CoV-2 infection, we recruited 68 convalescent individuals and 39 presumed unexposed controls selected randomly in a less-burdened region (greater area of Magdeburg, Germany, with less than 10 infections per 100 000 inhabitants at the time) (see Table 1 for patient characteristics). Serum and PBMCs were collected (mean: 101d, SD 37d) after positive SARS-CoV-2 PCR test from nasopharyngeal swaps and/or at time of IgG antibody testing >12 ng/ml antibodies against S-protein of SARS-CoV-2. All convalescents (MC) had mild symptoms during acute infection with SARS-CoV-2 (Table 1 ). In addition, twelve acute severe COVID-19 patients (ICU) were enrolled from ICU and 10 of them required ventilation-aided breathing. None of convalescent or unexposed donors had a history of rheumatic diseases or CD.

So far, in severely COVID-19 patients autoantibodies against multiple targets have been correlated with inflammation and/or mortality [5, 6] . To assess the relation between SARS-CoV-2

infections and the occurrence of autoantibodies in 68 mild COVID-19 convalescents against mucosalassociated autoantibodies, we monitored specific predictors for RA such as rheumatoid factor (RF) and anti-CCP autoantibodies ( Fig. 1A and B). The serum levels of RF in specimens from the convalescent patients (MC) did not show any significant difference than those found in healthy J o u r n a l P r e -p r o o f donors (HD) or those with acute disease (ICU) (Fig. 1A left) . The levels were also similar to those noted in autoimmune-prone donors who were > 50 years of age (data not shown). Anti-CCP autoantibodies that were not increased in acute severe COVID-19 patients [26] , however, were elevated specifically (p=0.0357) in convalescents when compared to unexposed donors (Fig. 1A right). These anti-CCP antibodies remained elevated in convalescents even after 8 months post infection (p=0.0165) (Fig. 1B) . Anti-CCP antibody levels did not result from smoking in this particular patient group (Fig. 1C left) . Interestingly, together with elevated anti-CCP antibody levels in the sera from the convalescents these individuals showed a significant higher frequency of anti-CCPassociated HLA-DRB1*04 shared epitope alleles in comparison to the anti-CCP negative donors [27] (10/55 vs. 6/13, p=0.043) that could further contribute the development of RA [28] (Fig. 1C right) . To exclude inflammation causing high antibody levels in convalescents [29] , we confirmed resolved inflammatory processes by low calprotectin concentrations in these sera (Fig. 1D ). In conclusion, these data reveal a link between SARS-CoV-2 infections and anti-CCP specific autoantibody levels that become and remain detectable during convalescence phase.

We next examined the potential role of the immune response to SARS-CoV-2 to the presence of autoimmune antibodies in the sera of the convalescent and the acutely ill patients. According to the cutoff value these sera contained no (less than 12 ng/ml) or positive concentrations with more than 12 ng/ml of antibodies against S-protein of SARS-CoV-2 ( Fig. 1E, As autoimmune diseases such as RA commonly show peak manifestation after the age of 50 [30] , we grouped donors accordingly. Intriguingly, concentrations of anti-S IgG were positively associated with age (R 2 =0.15; p=0.0003) in anti-S antibody positive convalescents (Fig. 1E, left) indicating a possible association like autoimmune diseases to age. When grouping convalescents with J o u r n a l P r e -p r o o f anti-S IgG responses by age, the mean concentration was more than doubled in the adults being 50 years and older (mean 55.10 ng/ml, SD 54.98 ng/ml) compared with being below 50 years (mean 21.25 ng/ml, SD 12.43 ng/ml) (p=0.0067) (Fig. 1E right) . Additionally, anti-N IgG titers even showed a stronger age-correlation (Fig. 1G) . Furthermore, the capacity of the serum of anti-S IgG positive convalescents to inhibit viral binding to ACE2 was significantly enhanced in those above 50 years of age (mean (<50) 31.96% SD 29.03%; mean (>50) 60.52%, SD 26.87%, p=0.01) (Fig. 1F ). Of note, neither anti-S nor anti-N IgG levels of acute severe patients (ICU) correlated with age (data not shown) and the variety of anti-SARS-CoV-2 antibodies was not explainable by decay, while anti-S antibody levels remained stable and anti-N antibodies vanished over time (Fig. 1H ). Taken together, antibodies against SARS-CoV-2 structures especially were induced for long-term in convalescents being 50 years and older and prone to autoimmune diseases.

To analyze age dependent COVID-19 effects on T-cell subsets during convalescent phase, we determined absolute numbers of peripheral CD4 + naive T-cells (T N , CD4 + CD45RA + CCR7 + ), regulatory Tcells (T reg , CD4 + CD127 low CD25 high , data not shown), central memory T-cells (T CM , CD4 + CD45RO + CCR7 + ) [14] ex vivo from samples of former SARS-CoV-2-infected individuals that suffered mild symptoms ( Fig. 2A and B) . No significant correlation of T CM or naïve T cells appeared with age ( Fig. 2 A and B, left) , and neither of them correlated with anti-S antibody titers ( Fig. 2A and B, right), respectively. To assess the post-infectious impact of SARS-CoV-2 on the responsiveness of CD4 + T-cell subpopulations, we conducted analysis of the T-cell surface surrogate markers KLRG1 for terminal differentiation and CTLA-4 for T-cell exhaustion [31] . In contrast to healthy unexposed donors that showed a correlation between age and CD4 + T-cells expressing KLRG1 (R 2 =0.10;

p=0.0455, data not shown) no age association of KLRG1 expression could be detected in the convalescents group (Fig. 2C) . However, CD4 + T cells of convalescents that expressed CTLA-4 on the surface, significantly increased by the age and were significantly higher in donors of 50 years and J o u r n a l P r e -p r o o f older when compared to younger ones (Fig. 2D) . Thus, even months after recovery, changes in frequencies of a T cell subset of convalescent SARS-CoV-2 infected individuals showed age associations compared to the healthy controls. This could indicate systemic post-infectious COVID-19 effects on the immune system, especially in autoimmune prone individuals above 50 years of age.

To determine whether beside anti-CCP antibodies additional autoantibodies were prevalent in convalescents, we monitored antibodies to a number of autoantigens that included cardiolipin, ANAs with all positive ones being women (Fig. 3A, sFig. 1D ). Levels of anti-β2-GPI and anti-cardiolipin remained low in both unexposed donors and COVID-19 convalescents (Fig. 3A, sFig. 1C ). However, mildly experienced convalescent and acute severe COVID-19 patients showed significantly increased levels of (p=0.002) autoantibodies against tissue transglutaminase (TG) (Fig. 3A and B) . In contrast to RF or anti-CCP antibody levels that showed no association to detected anti-SARS-CoV-2 antibodies, anti-TG titers were significantly increased in anti-S IgG positive convalescents (sFig. 1A, B left).

Intriguingly, anti-TG antibody levels were furthermore significantly higher in convalescents aged 50 years and older when compared to unexposed donors of this age group (sFig. 1B right) in a rather gender balanced appearance (sFig. 1F). Most importantly, anti-TG antibody levels remained elevated even after 8 months post SARS-CoV-2 infection (Fig. 3C ). In general, the convalescent group showed significantly more frequent co-occurring autoantibodies when compared to unexposed donors (p=0.031) (Fig. 3D) . Strikingly, 85% of all anti-CCP positive convalescents expressed also elevated anti-TG antibody levels, compared to 0% in unexposed donors (Fig. 3E) . Notably, positive anti-CCP and TG J o u r n a l P r e -p r o o f antibody levels in convalescents appeared to be independently from the symptom loss of smell and further these patients showed no different distribution of gender and BMI compared to healthy unexposed controls (sFig. 1E-G).

Although previous reports have indicated a correlation between the presence of antiphospholipid antibodies (aPL) and severity of COVID-19 disease [32] , the present studies failed to note such a correlation including a lack of correlation of such autoantibodies in sera from convalescent as compared with healthy controls (sFig. 1C). Of note, none of the autoimmune antibody titers correlated by themselves with anti-SARS-CoV-2 antibody levels (data not shown).

Together, these data identify a co-occurrence of autoantibodies in COVID-19 patients and convalescents especially for anti-CCP and anti-TG antibodies that raised concerns of selective induction of long lasting autoimmune reactions resulting from SARS-CoV-2 infections.

As anti-TG antibody levels were detected to be significantly enhanced in convalescents being anti-S IgG positive or aged 50 years and older we sought to assess a relationship of an anti-TG response with further SARS-CoV-2 immune related parameters in these donors by using linear multi regression modeling ( Table 2 ). The analysis resulted in the inclusion of the ex vivo ratio of CD4 + to CD8 + T-cells, indicating that upon SARS-CoV-2 infection peripheral CD4 and CD8 compartments may have been differently replenished. Further, CTLA-4 expression on the surface of CD4 + T cells was a relevant parameter, as CTLA-4 expression implies immune exhaustion with age of convalescents ( Fig. 2D) and CTLA-4 + T cells persist at the site of chronic inflammation [33] . Using multiple regression, coefficients were p=0.045, p=0.017, p=0.065, respectively. The overall model fit was 

To answer the intriguing question whether mild SARS-CoV-2 infections could trigger long-term autoimmune events that can be detected during convalescent phase, our prospective study demonstrates that indeed in former SARS-CoV-2 infected individuals that suffered mild symptoms elevated autoantibody levels and rare diagnostic patterns on HEp2 cells (ANA) actually persist months later. This long-lasting effects appear similar to those persistent antibody and T-cell responses observed in acute COVID-19 patients [34] . The induction of autoimmune events has been frequently monitored as a common event during acute viral infections and anti-viral antibodies have been shown to react against tissue antigens [35] . In case of SARS-CoV-2 infection with lifethreatening COVID-19, acute autoimmunity against IFNs and phospholipids has been observed [5, 6] .

Here we report for the first time the unexpected finding of specifically enhanced autoimmune responses against CCP and TG even eight months after recovery from mild COVID-19, which could cause long-lasting autoimmune symptoms.

Anti-CCP antibodies that specifically predict the onset of RA occurred often in the group aged below 50 years. This age-relation was different from the common average age onset in the population that is 56 years in Germany [17] . Similarly, a shift in age incidence due to acute severe infections and in particular with SARS-CoV-2 has been suggested from another autoimmune disease that is KD in childhood [9, 36] . Therefore, SARS-CoV-2 infections accompanied with mild symptoms likely could trigger anti-CCP antibody responses. The citrullination of proteins that is enhanced by inflammation could aim for marking abundant SARS-CoV-2 proteins, which in turn supports generation of anti-CCP antibodies. People who are already susceptible for developing RA probably J o u r n a l P r e -p r o o f release a rather pronounced inflammatory response against SARS-CoV-2 infections. This is in line with an associated susceptibility of RA patients to infections especially in the respiratory tract [37, 38] . This would also be conform with enhanced autoantibodies to IFNs in acute COVID-19 patients, which likely have been preexisted already at disease onset [4] . Since RA is strongly associated with certain HLA loci, which we detected to be present in those individuals showing elevated anti-CCP antibody titers [27] , it is tempting to speculate that especially those with genetic predisposition will be affected to develop overt disease. Nevertheless, the enhanced co-autoimmunity especially as 85% of anti-CCP antibody positive convalescents also express anti-TG antibodies, which is not observed in unexposed donors, indicate SARS-CoV-2 infections as a shared environmental factor in their induction. In addition, using regression analysis, we report that the appearance of anti-TG autoantibodies in convalescents >50 years of age is related to anti-S antibody levels ( Table 2) pointing towards a specific feature of an overt SARS-CoV-2 infection. Furthermore, the increased CTLA-4 expression in these convalescents indicates a cellular exhaustion phenotype and therefore overcoming the SARS-CoV-2 infection preferentially depends on antibody-mediated mechanisms. The failure to detect antibodies in some convalescents could be explained as that these individuals likely resolved their SARS-CoV-2 infections by an effective cellular adaptive immune response instead.

Our data show that patients recovered from mild SARS-CoV-2 infections exhibit an increased persistence of anti-TG antibodies. Although only few donors showed antibody levels that indicate an immediate onset of clinical symptoms, it is known that autoimmune antibodies can already be elevated below the pathological range to inevitably signal a disease progression [39] . Besides gluten and α-interferon our data are supporting the idea that SARS-CoV-2 indeed may trigger anti-TG expression [40] [41] [42] . Nevertheless, transient occurrence of anti-TG antibodies has been described in patients with type 1 diabetes at onset [43] .

Our data recommend to include the monitoring of serum antibodies against CCP and TG as biomarkers for the serological surveillance of SARS-CoV-2 convalescent individuals [44] . Interestingly, among all predictive biomarkers examined especially these two are co-expressed and both J o u r n a l P r e -p r o o f associated with inflammatory lung-involvement [18, 21] . Since SARS-CoV-2 uses the respiratory tract as entry site, we speculate that especially in the lung autoimmune events may help to control potentially life-threatening SARS-CoV-2 infections. Therefore, as the first entry site of an antigen matters profoundly, vaccination against SARS-CoV-2 i.m. [45] 

Supplementary data to this article can be found online, see below. J o u r n a l P r e -p r o o f 

• SARS-CoV-2 infections alter T-cell status and lung-associated autoimmune processes.

• CD4 + T cells of COVID-19 convalescents show age dependent increase of CTLA-4.

• Mild COVID-19 linked to long-term autoantibodies against CCP and transglutaminase.

• Enriched biomarkers for RA and CD indicate SARS-CoV-2 as a factor for pathogenesis.

A Novel Coronavirus from Patients with Pneumonia in China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19

Broadly-targeted autoreactivity is common in severe SARS-CoV-2 Infection. medRxiv the preprint server for health sciences

The sense of smell in systemic lupus erythematosus

SARS-CoV-2, the autoimmune virus

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders

Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia

Clinical and immunological features of severe and moderate coronavirus disease 2019

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity

Persistent cellular immunity to SARS-CoV-2 infection

Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis

Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19

joints and immunity against citrullinated proteins in rheumatoid arthritis

Increased mortality among men aged 50 years old or above with elevated IgA antitransglutaminase antibodies: NHANES III

COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention

Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study

Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression

Cell Survival Failure in Effector T Cells From Patients With Systemic Lupus Erythematosus Following Insufficient Up-Regulation of Cold-Shock Y-Box Binding Protein 1. Arthritis & rheumatology (Hoboken

COVID-19 convalescent plasma composition and immunological effects in severe patients

Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles

Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis

Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register

SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment

Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review

Impact of the CTLA-4/CD28 axis on the processes of joint inflammation in rheumatoid arthritis

Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection

Cytotoxic and viral neutralizing antibodies crossreact with streptococcal M protein, enteroviruses, and human cardiac myosin

The 2009 A (H1N1) influenza virus pandemic: A review

The mortality of rheumatoid arthritis

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study

Antifilaggrin antibodies within "normal" range predict rheumatoid arthritis in a linear fashion

Reovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease

Factors That Increase Risk of Celiac Disease Autoimmunity After a Gastrointestinal Infection in Early Life

Silent celiac disease in chronic hepatitis C: impact of interferon treatment on the disease onset and clinical outcome

Prevalence of celiac disease in children with type 1 diabetes mellitus increased in the mid-1990 s: an 18-year longitudinal study based on anti-endomysial antibodies

Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Columns represent donors and color intensities the level of the indicated autoantibodies. Donors were aligned according average linkage clustering method. B, Anti-tissue transglutaminase (TG) autoantibody levels of healthy unexposed donors (HD, open), convalescent (MC, blue), and acute severe (ICU, red) COVID-19 patients. C, Anti-TG antibody levels of negative (blue) and positive (violet) MC on mean day 93 after SARS-CoV-2 positive test and their anti-TG levels on mean day 227 (light blue and violet, respectively)